FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma
BACKGROUND: Prognosis of metastatic oesogastric adenocarcinoma (mOGC) beyond second‑line therapy remains poor. Trifluridine/tipiracil monotherapy is recommended in later lines but provides limited survival benefits. Anti‑angiogenic drugs have demonstrated significant efficacy in mOGC. Fruquintinib is a selective VEGFR‑1, ‑2 and ‑3 inhibitor with demonstrated activity in refractory colorectal adenocarcinoma. This design paper reports the rationale and design of the academic ENGIC 06 - PRODIGE 114 - FFCD 2401 - FRUQUITAS trial within the European network in gastro-intestinal oncology intergroup (ENGIC). METHODS: ENGIC 06 - PRODIGE 114 - FFCD 2401 - FRUQUITAS is an international, multicentre, open‑label, randomized phase III trial comparing trifluridine/tipiracil plus fruquintinib versus trifluridine/tipiracil alone in patients with metastatic oesophageal, gastro-oesophageal junction or gastric adenocarcinoma previously treated with two or three treatment lines. Patients are randomized 1:1 and stratified by treatment line, time from metastatic diagnosis to randomization, WHO performance status and prior anti‑angiogenic exposure. The primary endpoint is overall survival. Secondary endpoints include progression‑free survival, time to progression, objective response rate, disease control rate, safety, quality of life and translational biomarker analyses. PERSPECTIVES: ENGIC 06 - PRODIGE 114 - FFCD 2401 - FRUQUITAS is designed to determine whether VEGFR inhibition with fruquintinib plus trifluridine/tipiracil can meaningfully improve survival outcomes in pre-treated mOGC. TRIAL REGISTRATION: EU CT number 2025‑522395‑92‑00.
Authors
- Nadim Farés (ORCID: https://orcid.org/0000-0002-8954-3938)
- Mathilde Wagner (ORCID: https://orcid.org/0000-0003-1172-4592)
- Meriem Guarssifi
- Mélanie Dos Santos
- Tania Fleitas Kanonnikoff
- Pierre Laurent-Puig (ORCID: https://orcid.org/0000-0001-8475-5459)
- Emilie Soularue
- Karine Le Malicot (ORCID: https://orcid.org/0000-0002-3226-8525)
- Salah-Eddin Al-Batran
- Florian Lordick
- Ana Fernández Montes (ORCID: https://orcid.org/0000-0003-4630-5830)
- Fernando Rivera (ORCID: https://orcid.org/0000-0001-8915-226X)
- Julien Taieb
- Ulrich T. Hacker (ORCID: https://orcid.org/0000-0002-3253-8206)
- David Tougeron (ORCID: https://orcid.org/0000-0002-8065-9635)
- Thomas Aparicio (ORCID: https://orcid.org/0000-0001-8834-6927)
Institutions
- Délégation Paris 5 (FR)
- Inserm (FR)
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- Université Paris Cité (FR)
- Saint Louis University Hospital (US)
- Université de Poitiers (FR)
- Sorbonne Université (FR)
- Institute Mutualiste Montsouris (FR)
- Centre de Recherche des Cordeliers (FR)
- Hospital Clínico Universitario de Valencia (ES)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre François Baclesse (LU)
- Hôpital Européen Georges-Pompidou (FR)
- Instituto de Investigación Marqués de Valdecilla (ES)
- Fédération Francophone de Cancérologie Digestive (FR)
- Pitié-Salpêtrière Hospital (FR)
- Centre François Baclesse (FR)
- University Hospital Leipzig (DE)
- Krankenhaus Nordwest (DE)
- Complexo Hospitalario Universitario A Coruña (ES)
- Hôpital Saint-Louis (FR)
- INCLIVA Health Research Institute (ES)
- Complejo Hospitalario de Ourense (ES)
- Leipzig University (DE)
Publication Details
- Journal
- Digestive and Liver Disease
- Published
- 2026-05-01
- DOI
- https://doi.org/10.1016/j.dld.2026.04.004
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Takeda Pharmaceuticals U.S.A.
- Unicancer